Jubilant Life Sciences Ltd, an integrated global Pharmaceutical and Life Sciences Company, has announced that it has received Abbreviated New Drug Application (ANDA) final approval for
Rosuvastatin Calcium Tablets, 5 mg, 10 mg, 20 mg, and 40 mg, the generic version of Crestor® of IPR Pharmaceuticals, which is used for the treatment of hyperlipidemia or mixed dyslipidemia.
The Company has received 7 approvals from the USFDA during the year. As on September 30, 2016, Jubilant Life Sciences had a total of 72 ANDAs for Oral Solids filed in the US, of which 47 have been approved.
About Jubilant Life Sciences Limited
Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions. The Pharmaceuticals segment, through its wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile and Non-sterile products through 6 USFDA approved manufacturing facilities in India, USA and Canada. The Life Science Ingredients segment, is engaged in Specialty Intermediates, Nutritional Products and Life Science Chemicals through 5 manufacturing facilities in India. The Drug Discovery Solutions segment, provides proprietary in-house innovation & collaborative research and partnership for out-licensing through 3 world class research centres in India and USA. Jubilant Life Sciences Limited has a team of around 6,600 multicultural people across the globe and is committed to deliver value to its customers across over 100 countries. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals and life sciences companies globally. For more info: www.jubl.com.